Combination vaccine against various HIVs and combination method thereof

A technology for HIV and combination vaccines, used in antiviral agents, pharmaceutical formulations, antibody medical ingredients, etc.

Inactive Publication Date: 2009-11-04
VACDIAGN BIOTECH
View PDF2 Cites 14 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the effectiveness of this strategy also needs to be verified by future clinical trials.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combination vaccine against various HIVs and combination method thereof
  • Combination vaccine against various HIVs and combination method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0038] In a mouse model, the combination of gp140 and gp145 derived from the B' subtype activated a broad spectrum of neutralizing antibodies against multiple subtypes of HIV. After the recombinant DNA vaccine (named sv140 or sv145, inoculated three times) and recombinant vaccinia (named rTTV140 or rTTV145, inoculated once) were constructed, female BALB / c mice were immunized according to the procedures in Table 1, and 3 weeks after the immunization Neutralizing antibody testing was performed. In order to ensure the repeatability of the mouse neutralization experiment, equal volumes of serum from all mice in each vaccine immunization group were mixed for detection. Self-isolated HIV-1 virus strains (1 laboratory strain SF33, 1 HIV-1B` clinical isolate, 3 HIV-1B` / C clinical isolates) were used for neutralization test detection. The method refers to the operation procedure of Professor David C. Montefiori's laboratory at Duke University (Protocol for Measuring Neutralizing Antib...

Embodiment 2

[0043] Combining immunization with subtype C-derived gp140 and gp145 activated a broad spectrum of neutralizing antibodies against multiple subtypes of HIV in a mouse model. The method is as described in Example 1, and the results are shown in Table 2. The sv140+rTTV140 immunization group has no neutralizing activity against any HIV-1 virus strain; Neutralizing activity of subtype C isolate BC-1. The mouse sera from the two sequence cross-immunization groups showed high and broad-spectrum neutralizing antibody activity, especially the serum from the sv145+rTTV140 immunization group could neutralize the three viruses of laboratory strains SF33, BC-1, and BC-4 strain, and its titer can reach more than 1:60.

[0044] Table 2. Titers of sera of mice immunized with different combinations of vaccines at 50% virus suppression

[0045] HIV-1 strain

Embodiment 3

[0047] Combining gp140 and gp145 derived from subtype C immunization activated a broad spectrum of neutralizing antibodies against multiple subtypes of HIV in a guinea pig model. Method is as described in embodiment one, and result is as follows figure 2 As shown, the corresponding test results of serum collected at 6 weeks showed that all immunization groups had a certain neutralization effect, and half of the guinea pigs in all experimental groups could neutralize all isolates of HIV-1; but the sequential immunization group still neutralized The activity was better, about 3 / 4 guinea pigs in each group could neutralize all clinical isolates.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a combination vaccine against various HIVs and a combination method thereof. The combination vaccine consists of two or more HIV vaccines, different AIDS vaccines contain different HIV membrane proteins or membrane protein encoding genes, and each HIV vaccine is independently inoculated and inoculated at least one time, namely the total times of inoculation are at least twice. The core of the technology is that the different HIV membrane proteins are used to carry out sequential immunization, namely in sequential repeated immune processes of the vaccines, the HIV membrane proteins used in the immunization at different times are different so as to obtain a broad-spectrum neutral antibody against the HIVs with high titer. The HIV preventing vaccine developed by the method can be used for preventing various subtype HIV infections.

Description

technical field [0001] The invention relates to the technical field of HIV transmission prevention, in particular to a combination vaccine against multiple HIV and its combination method. Background technique [0002] Developing an effective AIDS vaccine is one of the current urgent tasks. Due to the genetic diversity of HIV (Human Immunodeficiency Virus, HIV), the continuous mutation of genes and multiple immune escape mechanisms, the development of effective AIDS vaccines has become the most important challenge facing mankind today. In 2003, VaxGen completed two Phase III clinical trials in homosexuals in Europe and the United States and drug users in Thailand. They tested a single B subtype gp120 or two subtypes B and E gp120 as immunogens, and mainly activated neutralizing antibodies. AIDS vaccines, but all ended in failure; following the failure of this clinical trial, another phase III clinical trial of a larger AIDS vaccine is currently underway. In this trial, 16,0...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/295A61K39/21A61K48/00A61P31/18
Inventor 徐建青万延民
Owner VACDIAGN BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap